NCT06385925
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
At risk: Primary completion moved 12 months later, primary endpoint(s) modified.
See at-risk trials from Tyligand Pharmaceuticals (Suzhou) Limited
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Oct 30, 2026 to Oct 30, 2027 Show 8 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 56 words
- Enrollment increased: 440 → 570 participants
- Trial sites expanded: 19 → 24 locations
- Study completion pushed from Apr 30, 2027 to Apr 30, 2028
- Interventions modified
- Trial arms changed: 5 → 7
- Study description expanded, about 1 word
Notable Enrollment target: 150 to 440v6 Show 5 more changesShow less
- Eligibility criteria expanded, about 64 words
- Study sites: 6 to 19
- Interventions: TSN1611 (Drug) to TSN1611 (Drug), TSN1611 (Drug), TSN1611 (Drug), TSN1611 (Drug)
- Study description expanded, about 85 words
- Study arms: 2 to 5
- Notable Lead sponsor: Tyligand Bioscience (Shanghai) Limited to Tyligand Pharmaceuticals (Suzhou) Limited
- Site contacts updated at 3 of 6 sites
- Minor Study sites: 3 to 6v4
- Minor Start date changed from estimate of Apr 30, 2024 to Apr 29, 2024
- Site details revised at 1 of 3 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.
Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.
Cohort A: TSN1611 combined with cetuximab treating subjects with advanced solid tumors harboring KRAS G12D mutation:
Cohort B: TSN1611 combined with GnP regimen (i.e., gemcitabine and nab-paclitaxel) treating subjects with advanced PDAC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.
Cohort C: TSN1611 combined with cetuximab and mFOLFOX6 regimen (i.e., fluorouracil, leucovorin, oxaliplatin) treating subjects with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.
Cohort D: TSN1611 combined with cetuximab and FOLFIRI regimen (i.e., fluorouracil, leucovorin, irinotecan) treating participants with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting. When the enrollment is active for both Cohort C and Cohort D simultaneously, participants could be allocated to either cohort alternatively (e.g., through randomization method), unless contradicted to either cohort.
The phase 1b part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.
Drugs: TSN1611
Sites
24 sites in 2 countries
China 21, United States 3